EP2326330A1 - Compositions for treating or delaying the onset of hair loss - Google Patents

Compositions for treating or delaying the onset of hair loss

Info

Publication number
EP2326330A1
EP2326330A1 EP09815103A EP09815103A EP2326330A1 EP 2326330 A1 EP2326330 A1 EP 2326330A1 EP 09815103 A EP09815103 A EP 09815103A EP 09815103 A EP09815103 A EP 09815103A EP 2326330 A1 EP2326330 A1 EP 2326330A1
Authority
EP
European Patent Office
Prior art keywords
pyrimidine
nbi
dihydro
oxo
hair
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP09815103A
Other languages
German (de)
French (fr)
Other versions
EP2326330A4 (en
EP2326330B1 (en
Inventor
Kiminobu Sugaya
Stephanie Merchant
Sergey Bushnev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Central Florida Research Foundation Inc
Original Assignee
University of Central Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Central Florida Research Foundation Inc filed Critical University of Central Florida Research Foundation Inc
Publication of EP2326330A1 publication Critical patent/EP2326330A1/en
Publication of EP2326330A4 publication Critical patent/EP2326330A4/en
Application granted granted Critical
Publication of EP2326330B1 publication Critical patent/EP2326330B1/en
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • Alopecia affects millions of men and women annually. 95 % of all hair loss is caused by Androgenic Alopecia (a genetically inherited hair loss condition, otherwise known as pattern baldness). The remaining 5% of hair loss can be associated with a variety of health conditions, stress and trauma, diet and nutrition, environmental toxins, and medications. Currently, five out of 10 men and 21 million women will experience hair loss and the psychological affects associated with this condition. In the case of Androgenic Alopecia, testosterone is converted in the body to DHT (Di- hydrotesterone) by the enzyme 5AR (5 Alpha-deductase).
  • DHT Di- hydrotesterone
  • 5AR Alpha-deductase
  • DHT binds to specific points in the hair follicle called Androgen Receptor Sites (ARS) and this causes a mineralization which shrinks the diameter of the hair and reduces the time spent in the growth cycle, known as the anagen phase.
  • ARS Androgen Receptor Sites
  • Other known types of hair loss can be diagnosed as Telogen Effiuvium, Traction or Traumatic Alopecia, Alopecia Areata, and Postpartum Alopecia. Telogen Effiuvium produces a premature shedding of hair that is in resting or telogen phase. causess of Telogen Effiuvium can be contributed to illness, shock, and medication and can usually be reversed upon the removal of conditions.
  • Alopecia Areata produces round irregular patchy spots of hair loss and the cause is unknown. But the commonality of all types of hair loss is the psychological effect it has on the men and women who experience these conditions.
  • FIG. 1 The pictures A-D are 20 uM sagittal sections of the dermal layer of mouse #1 A)Control (50% ETOH) at 1OX B; stained with anti-BrdU (green) 1.5 mg/ml NBI-18 at 5X magnification; stained with anti- BrdU (green) and dapi (blue) C) 3.0 mg/ml NBI-18 at 1OX magnification; stained with anti-BrdU (green) D) 3.0 mg/ml NBI- 18 at 10X magnification; stained with anti-BrdU (green).
  • FIG. 2 Pictures A-C are all of mouse #4.
  • FIG. 3 Immunohistochemistry: below A) control B) 3.0 mg/ml (circled area above in C where there is demonstrative hair re-growth.
  • FIG. 4 shows predominant hair re-growth (in white circle) in mouse #2 (A) using a topical application of 3.0 mg/ml. B) mouse prior to experiment. C) shaved area (in white circle) Below show immunohistochemistry of 3.0 mg/ml (D) where an overwhelming number of BrdU positive (green) cells coincides with the area of hair re-growth and 1.5 mg/ ml (E) where proliferation is at an increase.
  • NBI-18 (2-piperadino-6-methyl-5-oxo-5,6-dihydro-(7H) pyrrolo-[3,4-d] pyrimidine maleate; Mwt. 349.54), previously described as having possible neurotrophic activity, can stimulate the proliferation of human NSCs in culture.
  • the increase in proliferation was dose dependent in animal studies.
  • heterocyclic pyrrolopyrimidine (PyP) compounds have a variety of growth promoting biological activities including increasing neurite outgrowth and repair of injured peripheral nerves and muscle.
  • One derivative of interest is heterocyclic pyrimidine molecule referred to herein as 'NBI- 18' (2-piperadino-6-methyl-5-oxo-5,6-dihydro-(7H) pyrrolo-[3,4-d] pyrimidine maleate; Mwt. 349.54).
  • NBI-18 was reported to be active primarily in the presence of various growth factors, including bFGF, nerve growth factor, EGF, and insulin-like growth factor.
  • various growth factors including bFGF, nerve growth factor, EGF, and insulin-like growth factor.
  • MAPK mitogen activated protein kinase
  • NBI-18 promoted the survival of rodent cortical neurons by reducing the rate of apoptosis, as measured by TUNEL assays.
  • NBI-18 has been tested in isolated animal models-axon growth in mice and muscle regeneration in rats -- with no evidence of mechanistic details relating to function.
  • NBI-18 Keratinocyte Stem Cells
  • NBI-18 has proven to produce a desired affect in rodent models that show a predominant re- growth of hair using the topical application of the small molecular pyrimidine compound known as NBI-18.
  • NBI-18 treatment will lead to greater cytogenesis and eventually lead to a commercial product that will eradicate hair loss.
  • the subject invention pertains to a method of increasing thickness of hair (i.e. number of hair fibers per surface area) and/or number hair follicles actively producing hair fibers in a human or nonhuman subject that comprises the administration of a hair-enhancing composition that contains a hair producing agent (HPA).
  • HPA hair producing agent
  • U.S. Patent Nos. 5,976,523 ('523 patent) and 4,959,368 ('368 patent) teach a number of compounds that may be used as wound healing agents.
  • the '523 patent teaches that the wound healing agents described therein act by potentiating growth factors and cytokines released in tissues as a result of injury or wounding of tissues.
  • the '523 patent teaches that the agents stimulate the migration of cells toward the wound.
  • the present inventors have discovered that the same agents actually stimulate the proliferation of stem cells, which in turn, led to the discovery that the agents may be used in circumstances where tissues have not been wounded.
  • Typical illustrative compounds of formula (1) include:
  • Typical illustrative compounds of formula (2) include:
  • the pyrimidine derivative of formula (I) is NBI-18, or 2- piperadino-6-methyl-5-oxo-5,6-dihydro(7H) pyrrolo[2,3-d]pyrimidine maleate (the C 4 H 4 O 4 maleate salt), as disclosed in U.S. Pat. No. 4,959,368, incorporated by reference herein.
  • the pyrimidine derivatives of formulae (I) and (II) is administered at a concentration of between about 0.01 mg/kg/day to 50 mg/kg/day, more preferably between about 0.1 mg/kg/day to 10 mg/kg/day, even more preferably between about 1 mg/kg/day to 5 mg/kg/day, and even more preferably about 3 mg/kg/day.
  • the pyrimidine derivatives of formulae (I) and (II) is administered for between about 1 and 60 days, or more preferably between about 1 and 30 days, or more preferably between about 1 and 15 days, or even more preferably between about 1 and 10 days, or more preferably between about 2 and 7 days, or even more preferably about 5 days.
  • the methods further comprise the step of administering a growth factor.
  • the growth factor comprises fibroblast growth factor, epidermal growth factor or a combination thereof.
  • Pharmaceutical compositions comprising the active compounds of the invention may be manufactured by means of conventional mixing, dissolving, granulating, dragee-making levigating, emulsifying, encapsulating, entrapping or lyophilization processes.
  • the compositions may be formulated in conventional manner using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
  • the actual pharmaceutical composition administered will depend upon the mode of administration. Virtually any mode of administration may be used, including, for example topical, oral, systemic, inhalation, injection, transdermal, etc.
  • the active compound may be formulated in the pharmaceutical compositions per se, or in the form of a pharmaceutically acceptable salt.
  • pharmaceutically acceptable salt means those salts which retain substantially the biological effectiveness and properties of the active compound and which is not biologically or otherwise undesirable.
  • Such salts may be prepared from inorganic and organic acids and bases, as is well-known in the art. Typically, such salts are more soluble in aqueous solutions than the corresponding free acids and bases.
  • the active compound(s) may be formulated as solutions, gels, ointments, creams, suspensions, etc. as are well-known in the art.
  • Systemic formulations include those designed for administration by injection, e.g., subcutaneous, intravenous, intramuscular, intrathecal or intraperitoneal injection, as well as those designed for transdermal, transmucosal oral or pulmonary administration.
  • Useful injectable preparations include sterile suspensions, solutions or emulsions of the active compound(s) in aqueous or oily vehicles.
  • the compositions may also contain formulating agents, such as suspending, stabilizing and/or dispersing agent.
  • the formulations for injection may be presented in unit dosage form, e.g., in ampules or in multidose containers, and may contain added preservatives.
  • the injectable formulation may be provided in powder form for reconstitution with a suitable vehicle, including but not limited to sterile pyrogen free water, buffer, dextrose solution, etc., before use.
  • a suitable vehicle including but not limited to sterile pyrogen free water, buffer, dextrose solution, etc.
  • the active compound(s) may dried by any art-known technique, such as lyophilization, and reconstituted prior to use.
  • penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are known in the art.
  • the pharmaceutical compositions may take the form of, for example,tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulfate).
  • binding agents e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
  • fillers e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate
  • lubricants e.g., magnesium stearate, talc or silica
  • disintegrants e.g.,
  • Liquid preparations for oral administration may take the form of, for example, elixirs, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid).
  • the preparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.
  • Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
  • compositions may take the form of tablets, chewing gum or lozenges formulated in conventional manner.
  • the active compound(s) may be formulated as solutions (for retention enemas) suppositories or ointments containing conventional suppository bases such as cocoa butter or other glycerides.
  • the active compound(s) can be conveniently delivered in the form of an aerosol spray from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
  • the active compound(s) can be formulated as a depot preparation, for administration by implantation; e.g., subcutaneous, intradermal, or intramuscular injection.
  • the active ingredient may be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives; e.g., as a sparingly soluble salt
  • transdermal delivery systems manufactured as an adhesive disc or patch which slowly releases the active compound(s) for percutaneous absorption may be used.
  • permeation enhancers may be used to facilitate transdermal penetration of the active compound(s).
  • Suitable transdermal patches are described in for example, U.S. Pat.No. 5,407,713.; U.S. Pat. No. 5,352,456; U.S. Pat. No. 5,332,213; U.S. Pat. No. 5,336,168; U.S. Pat. No. 5,290,561 ; U.S. Pat. No. 5,254,346; U.S. Pat. No. 5,164,189; U.S. Pat. No. 5,163,899; U.S. Pat. No. 5,088,977; U.S. Pat. No. 5,087,240; U.S. Pat. No. 5,008,110; and U.S. Pat. No. 4,921 ,475.
  • Liposomes and emulsions are well-known examples of delivery vehicles that may be used to deliver active compounds(s).
  • Certain organic solvents such as dimethylsulfoxide (DMSO) may also be employed, although usually at the cost of greater toxicity.
  • DMSO dimethylsulfoxide
  • compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active compound(s).
  • the pack may, for example, comprise metal or plastic foil, such as a blister pack.
  • the pack or dispenser device may be accompanied by instructions for administration.
  • Example 1 Preparation of NBI-18 composition.
  • NBI-18 injections (5 mg/kg) increased proliferation of cells in the brain of rodents.
  • the inventors determined a dose range where keratinogenesis occurs in healthy mice to help us learn about the fate of newly formed cells within the epidermis.
  • This data enables selection of a relevant dose range for treating hair loss conditions such as Androgenic Alopecia, Alopecia Areata, Postpartum Alopecia and Telogen Effiuvium using a topical application.
  • Normal healthy C57 BL/6 mice exhibiting natural active behavior were used to test the topical application of NBI-18.
  • our vehicle of delivery was 50% Ethanol (ETOH).
  • NBI-18 was suspended in 50% ETOH using the concentrations of 0.75 mg/ml, 1.5 mg/ml, 3.0 mg/ml, and control (50%ETOH) respectively.
  • mice A total of 16 male C57 BL/6 mice (12 weeks old) weighing 25-30 g were used to investigate the toxicity of NBI-18. The mice were maintained on a 12-h light/dark cycle, and had free access to food and water through the study period. These animals were housed four per cage. In this study, animals were divided into four groups (four / group). Acute toxicity has been tested up to 1000 mg/kg. NBI-18 (0,100,300,1000 mg/kg/day, i.p.) was injected for 7 days and for the control group, the same volume of vehicle saline was injected.
  • Bromodeoxyuridine (BrdU)(Sigma Chemical Co., St Louis, Mo), was injected (100 mg/ kg/day, i.p.) for the last three days (days 5-7).
  • rotarod and open field tests were used to examine balance and coordination of mice before, during and after NBI-18 injection.
  • postural reflex and forelimb placing tests were performed to evaluate the neurological functions for the animals. All the animals were anesthetized with pentobarbital (i.p.) 48 h after the last BrdU injection and immediately per fused with 4% paraformaldehyde fixative. The brains were immediately dissected, post fixed for 24 h and processed for immunohistochemistry. [032] Results.
  • mice demonstrated no immediate behavioral or neurological changes in the study. They showed no symptoms of toxicity due to the treatment with NBI-18 throughout the experiment. An Ames was conducted by a third party company and the results were consistent showing no mutagenesis or toxicity, suggesting that NBI-18 is safe and won't have any adverse effects on the mice.
  • mice Two C57 BL/6 mice were selected for the topical application study of NBI- 18. The mice were prepped by shaving four specific locations lateral/dorsal in a circular pattern. NBI-18 was delivered to the specified areas (right, counterclockwise from lowest to highest dose, then control) in concentrations of 1.5 mg/ml, 3.0 mg/ml, 6.0 mg/ml and control (50%ETOH) respectively. The solutions were applied to the center of these locations in a 5 ul dose for 5 consecutive days and on days 4 and 5 BrdU (100 mg/K, ip) was injected. On day 7 the mice were euthanized using a high dose pentobarbital (70 mg/kg, ip) and the treated epidermis was dissected and placed into 4% paraformaldehyde fixative for 48 hour
  • mice Four C57 BL/6 mice were selected for the topical application study of NBI- 18. The mice were prepped by shaving four specific locations lateral/dorsal in a circular pattern. NBI-18 was delivered to the specified areas (right, counterclockwise from lowest to highest dose, then control) in concentrations of 0.75 mg/ml, 1.5 mg/ml, and 3.0 mg/ml, and control (50%ETOH) respectively. The solutions were applied to the center of these locations in a 5 ul dose for 5 consecutive days and on days 4 and 5 BrdU (100 mg/K, ip) was injected.
  • NBI-18 was delivered to the specified areas (right, counterclockwise from lowest to highest dose, then control) in concentrations of 0.75 mg/ml, 1.5 mg/ml, and 3.0 mg/ml, and control (50%ETOH) respectively. The solutions were applied to the center of these locations in a 5 ul dose for 5 consecutive days and on days 4 and 5 BrdU (100 mg/K, ip) was injected.
  • mice were euthanized using a high dose pentobarbital (70 mg/kg, ip) and the treated epidermis was dissected and placed into 4% paraformaldehyde fixative for 48 hour.
  • pentobarbital 70 mg/kg, ip
  • the treated epidermis was dissected and placed into 4% paraformaldehyde fixative for 48 hour.
  • Epidermal sections were mounted into square embedding molds with freezing medium (O. CT. compound, Tissue Tek), sliced in 2OuM sections then mounted onto adhesive coated slides (Instrumedics, Inc) via tape transfer method. Slides were washed with PBS then placed in 2N HCL for 30 minutes to induce histone release. Slides were then washed again with PBS, then blocked using 3% Donkey serum in PBST for 1 hour.
  • Telogen is the final phase often referred to as the "resting" or “off” phase and this is when the hair follicle renews or activates itself and a new hair in the anagen phase develops pushing the old hair out.
  • the mechanistic effect of NBI-18 has on the stem cell population and how it directly effects the hair follicles is still in the process of being elucidated.
  • Another study using the monoxidil showed that in animal studies, topical minoxidil shortens the telogen phase, causing premature entry of new hair from resting hair follicles into anagen phase, thus producing a mechanistic blocking effect of the natural pathways. In order to preserve this mechanistic effect, the delivery dosage must continually be maintained.
  • NBI-18 bypasses the ethical and technical issues associated with stem cell transplantation by directly coaxing the production of healthy new endogenous cells.
  • NBI-18 and its variants represent a unique class of synthetic heterocyclic compounds that are stable, orally bioavailability, and easily manufactured.
  • the inventors are able to use a compound that works synergistically with natural stem cell growth factors to speed up cell proliferation.
  • Such compounds are a rare and valuable therapeutic candidate. This idea delivers an exciting time for everyone. It is a new and innovative drug that could change the aesthetics of people everywhere. The adverse psychological effects caused hair loss will no longer be an in issue in both men and women.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed herein are novel methods and compositions for treating and/or preventing hair loss in patients. Specifically exemplified herein are compositions containing a modified pyrimidine that are topically applied to a scalp of an patient. Typically, the patient has androgenic alopecia, alopecia areata, postpartum alopecia or telogen effluvium.

Description

COMPOSITIONS FOR TREATING OR DELAYING THE ONSET OF HAIR LOSS
Cross reference to related applications
[01] This application is related to U.S. Provisional patent application no. 61/097,443; filed September 16, 2008 to which priority is claimed under 35 USC 119. This provisional application is incorporated herein in its entirety.
BACKGROUND
[02] Alopecia affects millions of men and women annually. 95 % of all hair loss is caused by Androgenic Alopecia (a genetically inherited hair loss condition, otherwise known as pattern baldness). The remaining 5% of hair loss can be associated with a variety of health conditions, stress and trauma, diet and nutrition, environmental toxins, and medications. Currently, five out of 10 men and 21 million women will experience hair loss and the psychological affects associated with this condition. In the case of Androgenic Alopecia, testosterone is converted in the body to DHT (Di- hydrotesterone) by the enzyme 5AR (5 Alpha-deductase). DHT binds to specific points in the hair follicle called Androgen Receptor Sites (ARS) and this causes a mineralization which shrinks the diameter of the hair and reduces the time spent in the growth cycle, known as the anagen phase. Other known types of hair loss can be diagnosed as Telogen Effiuvium, Traction or Traumatic Alopecia, Alopecia Areata, and Postpartum Alopecia. Telogen Effiuvium produces a premature shedding of hair that is in resting or telogen phase. Causes of Telogen Effiuvium can be contributed to illness, shock, and medication and can usually be reversed upon the removal of conditions. Traction or Traumatic Alopecia is demonstrated by patchy, scattered hair loss and is induced by heating elements used to dress hair or binding hair with bands; this is also reversible by removal of conditions. Alopecia Areata produces round irregular patchy spots of hair loss and the cause is unknown. But the commonality of all types of hair loss is the psychological effect it has on the men and women who experience these conditions. BRIEF DESCRIPTION OF DRAWINGS
[03] FIG. 1 The pictures A-D are 20 uM sagittal sections of the dermal layer of mouse #1 A)Control (50% ETOH) at 1OX B; stained with anti-BrdU (green) 1.5 mg/ml NBI-18 at 5X magnification; stained with anti- BrdU (green) and dapi (blue) C) 3.0 mg/ml NBI-18 at 1OX magnification; stained with anti-BrdU (green) D) 3.0 mg/ml NBI- 18 at 10X magnification; stained with anti-BrdU (green).
[04] FIG. 2 Pictures A-C are all of mouse #4. A) Prior to experiment (nothing has been done to the animal. B) The circled area shows where the hair has been shaved and what appears to look like a water drop is the application of solutions prior to evaporation (this picture was taken on the first day of application). C) The circled area shows where there was a predominant re-growth of hair.
[05] FIG. 3. Immunohistochemistry: below A) control B) 3.0 mg/ml (circled area above in C where there is demonstrative hair re-growth.
[06] FIG. 4: shows predominant hair re-growth (in white circle) in mouse #2 (A) using a topical application of 3.0 mg/ml. B) mouse prior to experiment. C) shaved area (in white circle) Below show immunohistochemistry of 3.0 mg/ml (D) where an overwhelming number of BrdU positive (green) cells coincides with the area of hair re-growth and 1.5 mg/ ml (E) where proliferation is at an increase.
DETAILED DESCRIPTION
[07] Recently, in the course of evaluating factors that influence stem cell proliferation, we made a provocative discovery. A heterocyclic pyrimidine molecule NBI-18 (2-piperadino-6-methyl-5-oxo-5,6-dihydro-(7H) pyrrolo-[3,4-d] pyrimidine maleate; Mwt. 349.54), previously described as having possible neurotrophic activity, can stimulate the proliferation of human NSCs in culture. The increase in proliferation was dose dependent in animal studies. We found that daily injections of NBI-18 for five days led to stable neurogenesis at four weeks in young and aged rodents alike. There were no discernible pathological effects, and no symptoms of toxicity due to the treatment with NBI-18 throughout the experiment. Based on these preliminary findings, we moved towards developing a topical application in an attempt to increase cell proliferation in a similar manner in relation to hair regeneration. C57 BL/6 mice were used to apply different concentrations of NBI-18 on shaved areas of skin with the incorporation of BrdU to detect cell proliferation, followed by immunohistochemistry. We were able to see an abundant increase in proliferating cells in all concentrations applied in comparison to the control area. More importantly, was the visibly complete hair growth that was in the treated areas compared to the non-treated areas. NBI-18 promises to be a novel compound leading to the development of regenerative therapeutics that can accelerate hair growth.
[08] Recently, the inventors became intrigued by several reports suggesting that a family of heterocyclic pyrrolopyrimidine (PyP) compounds have a variety of growth promoting biological activities including increasing neurite outgrowth and repair of injured peripheral nerves and muscle. U.S. Patent Nos. 4,959,368; 5,976,523. One derivative of interest is heterocyclic pyrimidine molecule referred to herein as 'NBI- 18' (2-piperadino-6-methyl-5-oxo-5,6-dihydro-(7H) pyrrolo-[3,4-d] pyrimidine maleate; Mwt. 349.54). In other cell culture studies using neurons isolated from rodent cortex, NBI-18 was reported to be active primarily in the presence of various growth factors, including bFGF, nerve growth factor, EGF, and insulin-like growth factor. U.S. Patent Pub 20030139410. The mechanism of action of NBI-18 is not known, although some evidence implies the activation of the MAPK (mitogen activated protein kinase) pathway, a cascade that is also activated by peptide growth factors. It has been suggested that NBI-18 promoted the survival of rodent cortical neurons by reducing the rate of apoptosis, as measured by TUNEL assays. NBI-18 has been tested in isolated animal models-axon growth in mice and muscle regeneration in rats -- with no evidence of mechanistic details relating to function. Mechanism of action studies to find the drug target, are planned as part of our ongoing research. Upon learning about the availability of NBI-18 family of molecules, it was hypothesized that the compounds may be involved in the proliferation process of Stem Cells and the inventors decided to examine the possible implication for genesis of Keratinocyte Stem Cells (KSCs) or possibly the human bulge cells which provide the niche for KSCs, in animal models. Early evidence from rodent studies, suggests that NBI-18 is absorbed well after intraperitoneal as well as oral administration and it has a t1/2 »4 h in rat circulation as shown by HPLC analysis. NBI-18 can be extracted 24 hours-post-injection from the epidermis of treated mice and the compound was not mutagenic, as indicated by a third party Ames test.
[09] Based on the inventors' realizations, the decision was made to test NBI-18 in a topical application study to induce the genesis or re-growth of hair. Varying doses of NBI-18 [0.75 mg/ml, 1.5 mg/ml, 3.0 mg/ml, and control (50%ETOH)] was delivered in 5 ul drops to shaved locations on the back of C57 BL/6 mice. The varying doses were given 5 consecutive days and on day 4 and 5 BrdU (100 mg/kg, ip) was injected, lmmunohistochemistry suggest a vast increase in Brdu + cells throughout the NBI-18 concentrations in comparison to the control, which didn't receive NBI-18. However, the most impressive data was the visible re-growth of hair in the treated areas, near to its original length within 7 days. The control or untreated areas showed no visible re-growth within the 7 day time frame. NBI-18 has proven to produce a desired affect in rodent models that show a predominant re- growth of hair using the topical application of the small molecular pyrimidine compound known as NBI-18. We are hypothesizing that NBI-18 treatment will lead to greater cytogenesis and eventually lead to a commercial product that will eradicate hair loss. These studies will be further described in the Examples provided below.
[010] Accordingly, in one embodiment, the subject invention pertains to a method of increasing thickness of hair (i.e. number of hair fibers per surface area) and/or number hair follicles actively producing hair fibers in a human or nonhuman subject that comprises the administration of a hair-enhancing composition that contains a hair producing agent (HPA). U.S. Patent Nos. 5,976,523 ('523 patent) and 4,959,368 ('368 patent) teach a number of compounds that may be used as wound healing agents. The '523 patent teaches that the wound healing agents described therein act by potentiating growth factors and cytokines released in tissues as a result of injury or wounding of tissues. Essentially, the '523 patent teaches that the agents stimulate the migration of cells toward the wound. The present inventors have discovered that the same agents actually stimulate the proliferation of stem cells, which in turn, led to the discovery that the agents may be used in circumstances where tissues have not been wounded.
[011] Accordingly, the agents presented in the '523 patent and '368 patent are incorporated herein by reference for disclosure of HPA agents. Also see U.S. Patent Pub 20080124306Formulas 1 and 2 as set forth in the '523 patent are provided:
(H
and
P)
wherein Ri to R8 independently represent a hydrogen atom, a lower alkyl (especially C1-C7 alkyl) group, CH3OCH2CH2-, -CH2CONH2, -COCH3, -COC2H5 or - CH2OCOC2H5, and X represents =NH, =N-CH3, =N-COCH3, =N-COOC2H5, =N- SO2CH3, =CH2, =CHCH3, =CHC2H5, -O- or -S- in which ph stands for a phenyl group.
Typical illustrative compounds of formula (1) include:
2-Piperazino-6-methyl-5-oxo-5,6-dihydro(7H)pyrro-[3,4-d]pyrimidine,
2-(4-Methylpiperazino-6-methyl-5-oxo-5,6-dihydro-(7H)pyrro[3,4 -d]pyrimidine,
2-(4-Ethylpiperazino-6-methyl-5-oxo-5,6-dihydro-(7H)pyrro[3,4-d]pyrimidine,
2-Piperidino-6-methyl-5-oxo-5,6-dihydro(7H)pyrro-[3,4-d]pyrimidine,
2-(4-Methylpiperidino)-6-methyl-5-oxo-5,6-dihydro(7H)pyrro[3,4-d]pyrimidine
2-(4-Ethylpiperidino)-6-methyl-5-oxo-5,6-dihydro-(7H)pyrro[3,4-d]pyrimidine
2-Morpholino-6-methyl-5-oxo-5,6-dihydro(7H)pyrro-[3,4-d]pyrimidine,
2-Thiomorpholino-6-methyl-5-oxo-5,6-dihydro(7H)-pyrro[3,4-d]pyrimidine,
2-Piperazino-6-ethyl-5-oxo-5,6-dihydro(7H)pyrro-[3,4-d]pyrimidine,
2-Piperazino-6-isopropyl-5-oxo-5,6-dihydro(7H)-pyrro[3,4-d]pyrimidine,
2-Piperazino-6-n-butyl-5-oxo-5,6-dihydro(7H)-pyrro[3,4-d]pyrimidine,
2-Piperazino-6-sec.-butyl-5-oxo-5,6-dihydro(7H)-pyrro[3,4-d]pyrimidine,
2-Piperazino-6-t-butyl-5-oxo-5,6-dihydro(7H)-pyrro[3,4-d]pyrimidine,
2-Piperazino-4,6-dimethyl-5-oxo-5,6-dihydro(7H)-pyrro[3,4-d]pyrimidine,
2-Piperazino-6,7-dimethyl-5-oxo-5,6-dihydro(7H)-pyrro[3,4-d]pyrimidine,
2-Piperazino-6,7,7-trimethyl-5-oxo-5,6-dihydro-(7H)pyrro[314-d]pyrimidine,
2-Piperidino-4,6-dimethyl-5-oxo-5,6-dihydro(7H)-pyrro[3,4-d]pyrimidine,
2-Piperidino-6,7,7-trimethyl-5-oxo-5,6-dihydro-(7H)pyrro[3,4-d]pyrimidine,
2-Piperazino-7-methyl-6-ethyl-5-oxo-5,6-dihydro-(7H)pyrro[3,4-d]pyrimidine, and
2-Piperazino-4-methyl-6-ethyl-5-oxo-5,6-dihydro-(7H)pyrro[3,4-d]pyrimidine.
Typical illustrative compounds of formula (2) include:
2-Piperazino-7-methyl-6-oxo-5,6-dihydro(7H)pyrro-[2,3-d]pyrimidine,
2-(4-Methylpiperazino)-7-methyl-6-oxo-5,6-dihydro(7H)pyrro[2,3-d]pyrimidine
2-(4-Ethylpiperazino)-7-methyl-6-oxo-5,6-dihydro-(7H)pyrro[2,3-d]pyrimidine
2-(4-N-Acetylpiperazino)-7-methyl-6-oxo-5,6-dihydro(7H)pyrro[2,3-d]pyrimidine,
2-Piperidino-7-methyl-6-oxo-5,6-dihydro(7H)pyrro-[2,3-d]pyrimidine,
2-(4-Methylpiperidino)-7-methyl-6-oxo-5,6-dihydro(7H)pyrro[2,3-d]pyrimidine 4-(Ethylpiperidino)-7-methyl-6-oxo-5,6-dihydro-(7H)pyrro[2,3-d]pyrimidine,
2-Morpholino-7-methyl-6-oxo-5,6-dihydro(7H)pyrro-[2,3-d]pyrimidine,
2-Thiomorpholino-7-methyl-6-oxo-5,6-dihydro(7H)-pyrro[2,3-d]pyrimidine,
2-Piperidino-7-ethyl-6-oxo-5,6-dihydro(7H)pyrro-[2,3-d]pyrimidine,
2-Piperidino-7-n-propyl-6-oxo-5,6-dihydro(7H)-pyrro[2,3-d]pyrimidine,
2-Piperidino-7-isopropyl-6-oxo-5,6-dihydro(7H)-pyrro[2,3-d]pyrimidine,
2-Piperidino-7-n-butyl-6-oxo-5,6-dihydro(7H)-pyrro[2,3-d]pyrimidine,
2-Piperidino-7-t-butyl-6-oxo-5,6-dihydro(7H)-pyrro[2,3-d]pyrimidine,
2-Piperidino-5-methyl-6-oxo-5,6-dihydro(7H)pyrro-[2,3-d]pyrimidine,
2-Piperazino-5-methyl-6-oxo-5,6-dihydro(7H)pyrro-[2,3-d]pyrimidine,
2-Piperazino-4,7-dimethyl-6-oxo-5,6-dihydro(7H)-pyrro[2,3-d]pyrimidine,
2-Piperidino-5,7-dimethyl-6-oxo-5,6-dihydro(7H)-pyrro[2,3-d]pyrimidine,
2-Piperidino-5,5,7-trimethyl-6-oxo-516-dihydro-(7H)pyrro[2,3-d]pyrimidine,
2-Piperazino-5,7-dimethyl-6-oxo-5,6-dihydro(7H)-pyrro[2,3-d]pyrimidine,
2-Piperazino-5,5,7-trimethyl-6-oxo-5,6-dihydro-(7H)pyrro[2,3-d]pyrimidine,
2-Piperidino-4-methyl-7-ethyl-6-oxo-5,6-dihydro-(7H)pyrro[2,3-d]pyrimidine, and
2-Piperidino-5-methyl-7-ethyl-6-oxo-5,6-dihydro-(7H)pyrro[2,3-d]pyrimidine.
[012] In certain embodiments the pyrimidine derivative of formula (I) is NBI-18, or 2- piperadino-6-methyl-5-oxo-5,6-dihydro(7H) pyrrolo[2,3-d]pyrimidine maleate (the C4H4O4 maleate salt), as disclosed in U.S. Pat. No. 4,959,368, incorporated by reference herein. In certain in vivo embodiments, the pyrimidine derivatives of formulae (I) and (II) is administered at a concentration of between about 0.01 mg/kg/day to 50 mg/kg/day, more preferably between about 0.1 mg/kg/day to 10 mg/kg/day, even more preferably between about 1 mg/kg/day to 5 mg/kg/day, and even more preferably about 3 mg/kg/day. In these embodiments, the pyrimidine derivatives of formulae (I) and (II) is administered for between about 1 and 60 days, or more preferably between about 1 and 30 days, or more preferably between about 1 and 15 days, or even more preferably between about 1 and 10 days, or more preferably between about 2 and 7 days, or even more preferably about 5 days. In certain others of these embodiments, the methods further comprise the step of administering a growth factor. In certain embodiments, the growth factor comprises fibroblast growth factor, epidermal growth factor or a combination thereof. [013] Pharmaceutical compositions comprising the active compounds of the invention may be manufactured by means of conventional mixing, dissolving, granulating, dragee-making levigating, emulsifying, encapsulating, entrapping or lyophilization processes. The compositions may be formulated in conventional manner using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. The actual pharmaceutical composition administered will depend upon the mode of administration. Virtually any mode of administration may be used, including, for example topical, oral, systemic, inhalation, injection, transdermal, etc.
[014] The active compound may be formulated in the pharmaceutical compositions per se, or in the form of a pharmaceutically acceptable salt. As used herein, the expression "pharmaceutically acceptable salt" means those salts which retain substantially the biological effectiveness and properties of the active compound and which is not biologically or otherwise undesirable. Such salts may be prepared from inorganic and organic acids and bases, as is well-known in the art. Typically, such salts are more soluble in aqueous solutions than the corresponding free acids and bases.
[015] For topical administration, the active compound(s) may be formulated as solutions, gels, ointments, creams, suspensions, etc. as are well-known in the art. [016] Systemic formulations include those designed for administration by injection, e.g., subcutaneous, intravenous, intramuscular, intrathecal or intraperitoneal injection, as well as those designed for transdermal, transmucosal oral or pulmonary administration.
[017] Useful injectable preparations include sterile suspensions, solutions or emulsions of the active compound(s) in aqueous or oily vehicles. The compositions may also contain formulating agents, such as suspending, stabilizing and/or dispersing agent. The formulations for injection may be presented in unit dosage form, e.g., in ampules or in multidose containers, and may contain added preservatives.
[018] Alternatively, the injectable formulation may be provided in powder form for reconstitution with a suitable vehicle, including but not limited to sterile pyrogen free water, buffer, dextrose solution, etc., before use. To this end, the active compound(s) may dried by any art-known technique, such as lyophilization, and reconstituted prior to use.
[019] For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are known in the art.
[020] For oral administration, the pharmaceutical compositions may take the form of, for example,tablets or capsules prepared by conventional means with pharmaceutically acceptable excipientssuch as binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulfate). The tablets may be coated by methods well known in the art with, for example, sugars or enteric coatings.
[021] Liquid preparations for oral administration may take the form of, for example, elixirs, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate. Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
[022] For buccal administration, the compositions may take the form of tablets, chewing gum or lozenges formulated in conventional manner.
[023] For rectal and vaginal routes of administration, the active compound(s) may be formulated as solutions (for retention enemas) suppositories or ointments containing conventional suppository bases such as cocoa butter or other glycerides. [024] For administration by inhalation, the active compound(s) can be conveniently delivered in the form of an aerosol spray from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
[025] For prolonged delivery, the active compound(s) can be formulated as a depot preparation, for administration by implantation; e.g., subcutaneous, intradermal, or intramuscular injection. Thus, for example, the active ingredient may be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives; e.g., as a sparingly soluble salt [026] Alternatively, transdermal delivery systems manufactured as an adhesive disc or patch which slowly releases the active compound(s) for percutaneous absorption may be used. To this end, permeation enhancers may be used to facilitate transdermal penetration of the active compound(s). Suitable transdermal patches are described in for example, U.S. Pat.No. 5,407,713.; U.S. Pat. No. 5,352,456; U.S. Pat. No. 5,332,213; U.S. Pat. No. 5,336,168; U.S. Pat. No. 5,290,561 ; U.S. Pat. No. 5,254,346; U.S. Pat. No. 5,164,189; U.S. Pat. No. 5,163,899; U.S. Pat. No. 5,088,977; U.S. Pat. No. 5,087,240; U.S. Pat. No. 5,008,110; and U.S. Pat. No. 4,921 ,475.
[027] Alternatively, other pharmaceutical delivery systems may be employed. Liposomes and emulsions are well-known examples of delivery vehicles that may be used to deliver active compounds(s). Certain organic solvents such as dimethylsulfoxide (DMSO) may also be employed, although usually at the cost of greater toxicity.
[028] The pharmaceutical compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active compound(s). The pack may, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration.
Example 1 : Preparation of NBI-18 composition.
[029] In preliminary studies, the inventors found that NBI-18 injections (5 mg/kg) increased proliferation of cells in the brain of rodents. In this study, the inventors determined a dose range where keratinogenesis occurs in healthy mice to help us learn about the fate of newly formed cells within the epidermis. This data enables selection of a relevant dose range for treating hair loss conditions such as Androgenic Alopecia, Alopecia Areata, Postpartum Alopecia and Telogen Effiuvium using a topical application. Normal healthy C57 BL/6 mice exhibiting natural active behavior were used to test the topical application of NBI-18. In order for us to eliminate unnecessary anesthesia, our vehicle of delivery was 50% Ethanol (ETOH). NBI-18 was suspended in 50% ETOH using the concentrations of 0.75 mg/ml, 1.5 mg/ml, 3.0 mg/ml, and control (50%ETOH) respectively.
[030] Results. In using 50% ETOH as our delivery vehicle we were able to demonstrate through immunohistochemistry, an increased population in BrdU positive stained cells. This visible increase was incurred in all concentrations of NBI- 18 and showed a dramatic elevation in BrdU positive stained cells in comparison to the control which received just 50% ETOH. Although the elevations in BrdU positive stained cells did not demonstrate a dose dependent increase as one would expect, this could be due to the probability of that each recurring application was not placed in exactly the same area on some of the mice. A more applicable delivery system will be developed in future studies.
Example 2: Toxicity Study.
[031] A total of 16 male C57 BL/6 mice (12 weeks old) weighing 25-30 g were used to investigate the toxicity of NBI-18. The mice were maintained on a 12-h light/dark cycle, and had free access to food and water through the study period. These animals were housed four per cage. In this study, animals were divided into four groups (four / group). Acute toxicity has been tested up to 1000 mg/kg. NBI-18 (0,100,300,1000 mg/kg/day, i.p.) was injected for 7 days and for the control group, the same volume of vehicle saline was injected. Bromodeoxyuridine (BrdU)(Sigma Chemical Co., St Louis, Mo), was injected (100 mg/ kg/day, i.p.) for the last three days (days 5-7). For behavioral testing, rotarod and open field tests were used to examine balance and coordination of mice before, during and after NBI-18 injection. Also, postural reflex and forelimb placing tests were performed to evaluate the neurological functions for the animals. All the animals were anesthetized with pentobarbital (i.p.) 48 h after the last BrdU injection and immediately per fused with 4% paraformaldehyde fixative. The brains were immediately dissected, post fixed for 24 h and processed for immunohistochemistry. [032] Results. The animals demonstrated no immediate behavioral or neurological changes in the study. They showed no symptoms of toxicity due to the treatment with NBI-18 throughout the experiment. An Ames was conducted by a third party company and the results were consistent showing no mutagenesis or toxicity, suggesting that NBI-18 is safe and won't have any adverse effects on the mice.
Example 3: In Vivo Study.
[033] A. Two C57 BL/6 mice were selected for the topical application study of NBI- 18. The mice were prepped by shaving four specific locations lateral/dorsal in a circular pattern. NBI-18 was delivered to the specified areas (right, counterclockwise from lowest to highest dose, then control) in concentrations of 1.5 mg/ml, 3.0 mg/ml, 6.0 mg/ml and control (50%ETOH) respectively. The solutions were applied to the center of these locations in a 5 ul dose for 5 consecutive days and on days 4 and 5 BrdU (100 mg/K, ip) was injected. On day 7 the mice were euthanized using a high dose pentobarbital (70 mg/kg, ip) and the treated epidermis was dissected and placed into 4% paraformaldehyde fixative for 48 hour
[034] lmmunohistochemistry of epidermis. Epidermal sections were mounted into square embedding molds with freezing medium (O. CT. compound, Tissue Tek), sliced in 2OuM sections then mounted onto adhesive coated slides (Instrumedics, Inc) via tape transfer method. Slides were washed with PBS then placed in 2N HCL for 30 minutes to induce histone release. Slides were then washed again with PBS, then blocked using 3% Donkey serum in PBST for 1 hour. Primary anti-body suspended in blocking solution used was anti-BrdU (sigma) at 1 :1000 overnight in 4C. Slide were washed 3X then placed in secondary anti-body suspended in blocking solution, FITC (Jackson ImmunoResearch) at 1 :500 for 2 hours at room temperature then washed with PBS. Slides were mounted using Vectashield with Dapi. Photographs were taken using an inverted fluorescent microscope (Leica, DMI 6000 B with Q-imaging Retiga exi camera). [035] Results. The Control (A) show a much reduced level of BrdU signaling along with a nonmigration pattern; the new cells are sporadic throughout the tissue sample. All of the NBI-18 treated samples (B-D) showed mass increases of newly developed cells but most importantly they demonstrated an alignment towards migration patterns. FIG. 1.
[036] B. Four C57 BL/6 mice were selected for the topical application study of NBI- 18. The mice were prepped by shaving four specific locations lateral/dorsal in a circular pattern. NBI-18 was delivered to the specified areas (right, counterclockwise from lowest to highest dose, then control) in concentrations of 0.75 mg/ml, 1.5 mg/ml, and 3.0 mg/ml, and control (50%ETOH) respectively. The solutions were applied to the center of these locations in a 5 ul dose for 5 consecutive days and on days 4 and 5 BrdU (100 mg/K, ip) was injected. On day 7 the mice were euthanized using a high dose pentobarbital (70 mg/kg, ip) and the treated epidermis was dissected and placed into 4% paraformaldehyde fixative for 48 hour. [037] lmmunohistochemistry of epidermis. Epidermal sections were mounted into square embedding molds with freezing medium (O. CT. compound, Tissue Tek), sliced in 2OuM sections then mounted onto adhesive coated slides (Instrumedics, Inc) via tape transfer method. Slides were washed with PBS then placed in 2N HCL for 30 minutes to induce histone release. Slides were then washed again with PBS, then blocked using 3% Donkey serum in PBST for 1 hour. Primary anti-body suspended in blocking solution used was anti-BrdU (sigma) at 1 :1000 overnight in 4C. Slide were washed 3X then placed in secondary anti-body suspended in blocking solution, FITC (Jackson ImmunoResearch) at 1 :500 for 2 hours at room temperature then washed with PBS. Slides were mounted using Vectashield with Dapi. Photographs were taken using an inverted fluorescent microscope (Leica, DMI 6000 B with Q-imaging Retiga exi camera).
[038] Results. In all of the mice there were some varying levels of increase in BrdU positive cells in comparison with the controls as shown in the immunohistochemistry. FIG. 3. However the most visible effect is the actual hair re-growth demonstrated in the pictures of the mice. FIG. 2 (mouse 4) and FIG. 4 (mouse 2). Even though the locations of hair re-growth occur sporadically throughout the three concentrations of NBI-18 (0.75 mg/ml, 1.5 mg/ml, 3.0 mg/ml.), there is absolutely no visible hair regeneration in the controls within the same time constraints. This can be explained by the probability of each recurring applications ability was placed in exactly the same area. A 5 ul drop onto the back of a moving mouse allows for a possible missed location involving topical applications. However, the data clearly demonstrates the differences between the control and compound. A next feasible step will be to test this compounds efficacy against similar proven compounds such as minoxidil (Rogaine).
[039] Discussion related to Examples 1-3. Preliminary studies have shown that NBI-18 increases the number of BrdU positive cells in mice that have received a 5 day consecutive topical application of 5 ul doses of 0.75 mg/ml, 1.5 mg/ml, 3.0 mg/ml and 50% ETOH (control). There are three cycles of hair growth; the anagen phase (the growing phase), the catagen phase (where hair stops growing) and the Telogen phase (which is the resting phase). The anagen phase last for appx.1000 days but can range from 2-6 years and it is considered the "on" phase or growing phase. The catagen phase lasts for only 1-2 weeks and during this phase the hair follicle shrinks and starts to die; this is known as the transitional phase. Telogen is the final phase often referred to as the "resting" or "off" phase and this is when the hair follicle renews or activates itself and a new hair in the anagen phase develops pushing the old hair out. The mechanistic effect of NBI-18 has on the stem cell population and how it directly effects the hair follicles is still in the process of being elucidated. However, another study using the monoxidil showed that in animal studies, topical minoxidil shortens the telogen phase, causing premature entry of new hair from resting hair follicles into anagen phase, thus producing a mechanistic blocking effect of the natural pathways. In order to preserve this mechanistic effect, the delivery dosage must continually be maintained. In comparison our compound works on the physiological pathway of the stem cell environment by increasing the proliferation of endogenous cells. Once this increase is achieved, usually within a 3-5 day treatment schedule there is no need to continue using the compound. [040] The small molecule NBI-18 bypasses the ethical and technical issues associated with stem cell transplantation by directly coaxing the production of healthy new endogenous cells. NBI-18 and its variants represent a unique class of synthetic heterocyclic compounds that are stable, orally bioavailability, and easily manufactured. The inventors are able to use a compound that works synergistically with natural stem cell growth factors to speed up cell proliferation. Such compounds are a rare and valuable therapeutic candidate. This idea delivers an exciting time for everyone. It is a new and innovative drug that could change the aesthetics of people everywhere. The adverse psychological effects caused hair loss will no longer be an in issue in both men and women.
[041] The disclosures of all cited patent documents, publications and references are incorporated herein in their entirety to the extent not inconsistent with the teachings herein. It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims.

Claims

1. A method of treating hair loss or delaying the onset of hair loss in a patient in need thereof comprising administering a therapeutically effective amount of an HPA,or a pharmaceutically acceptable salt thereof, to said patient.
2. The method of claim 1 , wherein said patient has androgenic alopecia, alopecia areata, postpartum alopecia or telogen effiuvium.
3. The method of claim 1 , wherein said administering comprises parenteral administration, topical administration and/or oral administration.
4. The method of claim 1 , wherein said administering comprises topical administration.
5. The method of claim 1 , wherein said HPA is NBI-18.
6. A method of increasing the number of hair follicles growing hair on a scalp of a patient comprising administering a therapeutically effective amount of an HPA,or a pharmaceutically acceptable salt thereof, to said patient.
7. The method of claim 6, wherein said patient has androgenic alopecia, alopecia areata, postpartum alopecia or telogen effiuvium.
8. The method of claim 6, wherein said administering comprises parenteral administration, topical administration and/or oral administration.
9. The method of claim 6, wherein said administering comprises topical administration.
10. The method of claim 6, wherein said HPA is NBI-18.
EP09815103.8A 2008-09-16 2009-09-16 Compositions for treating or delaying the onset of hair loss Not-in-force EP2326330B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9744308P 2008-09-16 2008-09-16
PCT/US2009/057134 WO2010033576A1 (en) 2008-09-16 2009-09-16 Compositions for treating or delaying the onset of hair loss

Publications (3)

Publication Number Publication Date
EP2326330A1 true EP2326330A1 (en) 2011-06-01
EP2326330A4 EP2326330A4 (en) 2011-08-31
EP2326330B1 EP2326330B1 (en) 2015-01-07

Family

ID=42039840

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09815103.8A Not-in-force EP2326330B1 (en) 2008-09-16 2009-09-16 Compositions for treating or delaying the onset of hair loss

Country Status (5)

Country Link
US (1) US8791128B2 (en)
EP (1) EP2326330B1 (en)
JP (1) JP5555922B2 (en)
CA (1) CA2736018C (en)
WO (1) WO2010033576A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010087527A1 (en) * 2009-01-29 2010-08-05 Akira Awaya Ultraviolet absorbers, and pharmaceutical compositions and cosmetics containing pyrimidine compounds for uv protection

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004928A1 (en) 1986-02-24 1987-08-27 Mitsui Petrochemical Industries, Ltd. Agents for treating neurophathy
JPH08325268A (en) * 1986-02-24 1996-12-10 Mitsui Petrochem Ind Ltd Pyrrolo [3,4-d] pyrimidine derivative
US5304555A (en) * 1987-08-26 1994-04-19 Mitsui Petrochemical Industries, Ltd. Pyrimidines and pharmaceutically acceptable salts thereof useful in treatment of neurological disorders
JPH09295946A (en) * 1995-05-16 1997-11-18 Mitsui Pharmaceut Inc Pharmaceutical composition
EP0743066A3 (en) 1995-05-16 1998-09-30 Mitsui Pharmaceuticals, Inc. Wound-healing agent
WO1998006422A1 (en) * 1996-08-13 1998-02-19 Fujisawa Pharmaceutical Co., Ltd. Hematopoietic stem cell proliferating agents
IL140040A0 (en) * 1998-06-03 2002-02-10 Guilford Pharm Inc N-linked sulfonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres
GB9904281D0 (en) 1999-02-24 1999-04-21 Reneuron Ltd Transplantation
IL148175A0 (en) 1999-08-18 2002-09-12 Gen Hospital Corp Methods, compositions and kits for promoting recovery from damage to the central nervous system
AU2003202988A1 (en) 2002-01-14 2003-07-30 The Board Of Trustees Of The University Of Illinois Use of modified pyrimidine compounds to promote stem cell migration and proliferation
WO2005040391A1 (en) 2003-10-27 2005-05-06 Murdoch Childrens Research Institute Compositions and methods for differentiating stem cells
CA2552503C (en) * 2004-01-06 2011-09-13 Taisho Pharmaceutical Co., Ltd. Pyrrolopyrimidine and pyrrolotriazine derivatives
WO2005085253A1 (en) * 2004-03-05 2005-09-15 Taisho Pharmaceutical Co., Ltd. Pyrrolopyrimidine derivatives
FR2870739B1 (en) * 2004-05-26 2008-05-16 Oreal USE OF LIF IN COSMETICS AND DERMATOLOGY
JP2007161585A (en) * 2004-06-25 2007-06-28 Taisho Pharmaceut Co Ltd Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino groups
EA011606B1 (en) 2004-07-14 2009-04-28 Эдуард Борисович Татулов METHODS OF OBTAINING AND USING A RECOMBINANT ALPHA-FETOPROTEIN
US7850960B2 (en) * 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
US20060257449A1 (en) * 2005-05-16 2006-11-16 Didier Billy Methods, compositions, systems, and devices for bone fusion
WO2006133876A1 (en) * 2005-06-17 2006-12-21 Dsm Ip Assets B.V. Use of pyrimidine derivatives for cosmetic purposes
KR100705981B1 (en) 2005-10-12 2007-04-10 주식회사 리제론 Hair loss prevention or hair growth promoting composition containing human growth hormone
JP4804935B2 (en) * 2006-01-31 2011-11-02 株式会社マンダム Hair growth and nourishing composition
US20080124306A1 (en) * 2006-11-28 2008-05-29 Kiminobu Sugaya Vigor Enhancement Via Administration of Pyrimidine Derivatives
JP5568221B2 (en) 2008-06-09 2014-08-06 富士機械製造株式会社 Electronic circuit component mounting system
MX364609B (en) * 2010-01-29 2019-05-02 Monosol Llc Improved water-soluble film having blend of pvoh polymers, and packets made therefrom.

Also Published As

Publication number Publication date
CA2736018A1 (en) 2010-03-25
JP2012502918A (en) 2012-02-02
EP2326330A4 (en) 2011-08-31
WO2010033576A1 (en) 2010-03-25
EP2326330B1 (en) 2015-01-07
JP5555922B2 (en) 2014-07-23
CA2736018C (en) 2015-11-03
US20110190320A1 (en) 2011-08-04
US8791128B2 (en) 2014-07-29

Similar Documents

Publication Publication Date Title
US6191125B1 (en) Small molecule pipecolic acid derivative hair growth compositions and uses
PT1096924E (en) Inhibitors of proteasomal activity for stimulating hair growth
EP1379269B1 (en) Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson's disease
US11077118B2 (en) Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
AU755426B2 (en) Methods of inducing hair growth and coloration
AU709454B2 (en) Carbon monoxide dependent guanylyl cyclase modifiers
US6274617B1 (en) Heterocyclic ester and amide hair growth compositions and uses
EP2326330B1 (en) Compositions for treating or delaying the onset of hair loss
AU764032B2 (en) Small molecule carbamate or urea hair growth compositions and uses
WO2010148094A1 (en) Methods and compositions for increasing trichogenic potency of dermal cells
AU767155B2 (en) Small molecule pipecolic acid derivative hair growth compositions and uses
WO2006032481A1 (en) Tetrodotoxin and its derivatives for the treatment of central-nervously derived neuropathic pain
US6172087B1 (en) N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
Datta et al. Effects of MIF-I and melatonin on novelty-induced defecation and associated plasma 11-OHCS and brain catecholamines
Genkova-Papazova et al. The 5-HT2 receptor antagonist ketanserine prevents electroconvulsive shock-and clonidine-induced amnesia
JP2002516842A (en) Hair growth compositions which are N-oxides of heterocyclic esters, amides, thioesters or ketones and methods of use thereof
US6271244B1 (en) N-linked urea or carbamate of heterocyclic thioester hair growth compositions and uses
Alphs et al. Schizophrenic Inpatients'
Merchant et al. A Heterocyclic Pyrrolopyrimidine Compound as a Possible Candidate for Topical Application to Induce Hair Restoration
AU764073B2 (en) N-linked urea or carbamate of heterocyclic thioester hair growth compositions and uses
MXPA00011850A (en) Small molecule pipecolic acid derivative hair growth compositions and uses
Endo et al. Glucocorticoid hypersecretion following intracerebroventricular injection of ethylcholine mustard aziridinium ion in rats
Kang et al. DA-8159 has erectile potentials much longer than the plasma half-life in a conscious rabbit model
MXPA00009614A (en) Combination effective for the treatment of impotence comprising a potassium-channel-opener and a cgmp elevator

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110314

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MERCHANT, STEPHANIE

Inventor name: SUGAYA, KIMINOBU

A4 Supplementary search report drawn up and despatched

Effective date: 20110803

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 17/14 20060101ALI20110728BHEP

Ipc: A61K 31/54 20060101AFI20110728BHEP

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20121024

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140718

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 705212

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150215

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602009028877

Country of ref document: DE

Effective date: 20150219

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20150107

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 705212

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150107

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150107

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150107

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150107

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150407

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150107

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150407

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150107

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150107

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150408

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150107

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150107

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150107

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150507

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602009028877

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150107

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150107

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150107

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150107

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150107

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20151008

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150107

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150107

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150916

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150107

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150107

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150930

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150930

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150916

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150107

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20090916

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150107

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150107

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150107

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150107

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150107

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20220217

Year of fee payment: 13

Ref country code: DE

Payment date: 20220215

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20220222

Year of fee payment: 13

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602009028877

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20220916

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220930

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230401

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220916